1. Introduction {#s0005}
===============

*Pelargonium sidoides* DC. (Synonym: *Pelargonium sidaefolium* (Thunb.) R. Knuth; Common names: Umckaloabo, Uvendle, Kalwerbossie, Khoaara e nyenyane; Family: Geraniaceae) is a perennial geophyte predominantly found in the Eastern Cape Province of South Africa and the Lesotho highlands. The plant is adapted to a wide altitudinal range, spanning from near sea level in the Eastern Cape to 2746 m in the Lesotho highlands ([@bib55]). The plant is widely used by local communities as a traditional medicine for curing various ailments, including diarrhoea, colic, gastritis, tuberculosis, cough, hepatic disorders, menstrual complaints and gonorrhoea ([@bib7], [@bib10]). The roots are also the main ingredient in a remedy used to treat a stomach ailment known as *instila* in infants ([@bib21]). Powdered plant materials which are soaked in water are used as a facial cream in the treatment of skin pimples ([@bib34]). This indicates that *Pelargonium sidoides* may exhibit antibacterial properties. Probably the most compelling ethnobotanical use of *Pelargonium sidoides* has been in the treatment of tuberculosis, which subsequently led to its introduction in Europe in the late 1890s ([@bib5], [@bib7]). The traditional ethno-veterinary applications of *Pelargonium sidoides* include the use of root decoctions as an anthelmintic remedy in calves ([@bib21]); boiled leaves to protect wounds against maggots; and the prevention of purging in horses ([@bib7]). An extract obtained by soaking the roots in water is administered orally in the treatment of dysentery in cattle ([@bib34]). Based on its medicinal properties in the treatment of respiratory-related ailments, *Pelargonium sidoides* has been formulated into phytopharmaceuticals, namely EPs^®^ 7630 (Umckaloabo^®^, Dr. Willmar Schwabe GmbH & Co. KG Pharmaceuticals, Germany) and Linctagon^®^ (Nativa, South Africa). The commercial success of Umckaloabo^®^ is attributed to numerous factors, including \>15 years of extensive scientific and clinical research ([@bib15]). On the other hand, only negligible research ([@bib6], [@bib50]) has been done to evaluate the efficacy and safety of Linctagon^®^ (which mainly contains 350 mg *Pelargonium sidoides*, 500 mg Vitamin C, 50 mg bromelain, 80 mg quercetin, 5 mg zinc). This review provides a synthesis of the state of scientific knowledge on the pharmacology and safety evaluation of *Pelargonium sidoides* as well as exploring the potential of plant biotechnology applications in its conservation.

2. Phytochemistry {#s0010}
=================

The extensive use of *Pelargonium sidoides* in traditional medicine coupled with its popularisation in modern medical systems in Europe have led to an upsurge in scientific exploration of its chemical composition in an effort to identify the active principles. This has resulted in a considerable body of literature exploring the phytochemical properties of *Pelargonium sidoides* ([@bib16], [@bib17], [@bib19], [@bib25], [@bib33], [@bib64]). Details of the phytochemistry of the plant were comprehensively summarised in an excellent review by [@bib28]. However, identification of individual chemical constituents responsible for specific pharmacological activities has remained largely elusive. The chemical constituents of the root ethanolic extract of the plant consist largely of oligo- and polymeric proanthocyanidins, which are based on gallocatechin and epigallocatechin moieties ([@bib72]). The pharmacological efficacy of *Pelargonium sidoides* has been partly attributed to the biological activity of highly oxygenated coumarins (7-hydroxy-5,6-di-methoxycoumarin; 6,8-dihydroxy-5,7-dimethoxycoumarin), gallic acid-derivatives, flavonoids, phenolic and hydroxycinnamic acid-derivatives ([@bib25], [@bib28], [@bib10]). Recently, 6-Methoxy-7-(sulfooxy)-2H-1-benzopyran-2-one and 6,8-Bis(sulfooxy)-7-methoxy-2H-1-benzopyran-2-one were identified in *Pelargonium sidoides* for the first time ([@bib19]). Most significantly, [@bib19] characterised two novel compounds, 7-Hydroxy-6-methoxy-8-(sulfooxy)-2H‑1-benzopyran-2-one and 8-Hydroxy-7-methoxy-6-(sulfooxy)-2H‑1-benzopyran-2-one ([Fig. 2](#f0010){ref-type="fig"}). These novel compounds have to be screened for pharmacological activity as they may represent the individual active constituents that have so far remained elusive.

3. Pharmacological properties {#s0015}
=============================

It is interesting to note that the repertoire of health conditions for which *Pelargonium sidoides* is used has expanded beyond the original traditional uses against gastrointestinal disorders to include respiratory tract infections such as acute bronchitis, asthma, sinusitis and tonsilllopharyngitis. Accordingly, most of the experimental and clinical research has focused on the treatment of respiratory tract infections in line with the development of the phytopharmaceutical, EPs^®^ 7630 (Umckaloabo^®^). In this regard, a wide array of pharmacological studies involving *in vitro* ( [Table 1](#t0005){ref-type="table"}), *in vivo* ( [Table 2](#t0010){ref-type="table"}) and randomised, double-blind, placebo-controlled clinical trials ( [Table 3](#t0015){ref-type="table"}) has been conducted. Concomitantly, a diverse range of test systems has been used to evaluate the pharmacological properties of *Pelargonium sidoides*. The approaches, which are characterised by different levels of complexity, including the antimicrobial microdilution assay, anti-adhesion assay using HEp-2 cells, penicillin/gentamicin-protection assay, neuraminidase inhibition assay, fibroblast-virus protection assay and reverse transcription-polymerase chain reaction (RT-PCR) assay have helped in deciphering the pharmacological efficacies as well as the possible modes of action involved in the healing processes.Table 1Evaluation of the pharmacological activities of *Pelargonium sidoides* DC. using *in vitro* methods.**Biological activity (Test assay)Extract/formulationTest organismObserved activity and effective concentrationPossible mode of actionControlReference**Antiviral activity (Neuraminidase inhibition assay)[a](#tbl1fna){ref-type="table-fn"}EPs^®^ 7630H1N1 A/Puerto Rico/8/34EPs^®^ 7630=5.4 µg/ml (EC~50~); EPs^®^ 7630 (121.7 µg/ml) reduced neuraminidase activity by 50%Interference with virus binding to host cell receptors--[@bib72]Oligo-/polymeric fraction=2.8 µg/ml (EC~50~)Gallocatechin-(4β→8)\_gallocatechin=7.3 µg/ml (EC~50~)Epigallocatechin-(4β→8)\_gallocatechi*n*=6.3 µg/ml (EC~50~)Epigallocatechin=42.5 µg/ml (EC~50~)Gallocatechin=28.4 µg/ml (EC~50~)H3N2 A/Luxembourg/ 01/2005EPs^®^ 7630=50 µg/ml (EC~50~)Anti-viral activity (Cytopathogenic effect reduction assay)EPs^®^ 7630H1N1 A/New Caledonia/20/99IC~50~=9.45 µg/mlInhibition of viral replication--[@bib49]H3N2 A/California/7/2004IC~50~=8.66 µg/mlInhibition of viral replicationRSV ATCC-No. VR-1540IC~50~=19.65 µg/mlInhibition of viral replicationHuman coronavirus HCo-229EIC~50~=44.50 µg/mlInhibition of viral replicationParainfluenza virus 3 ATCC-No. VR-93IC~50~=74.35 µg/mlInhibition of viral replicationCoxsackie A9 virus (isolated from a patient)IC~50~=14.80 µg/mlInhibition of viral replicationH5N1 A/Thailand/1(Kan-)/04IC~50~\>100 µg/ml--Adenovirus 3 GB ATCC-No. VR-3IC~50~\>100 µg/ml--Adenovirus 7 strain Gomen ATCC-No. VR-7IC~50~\>100 µg/ml--Human rhinovirusIC~50~\>100 µg/ml--Antiviral activity (Fibroblast/EMCV protection assay)EPs^®^ 7630Encephalomyocarditis virus (EMCV)EPs^®^ 7630 (10 µg/ml)=80 U/mlInhibition of Cytopathic effectLPS (1.0 ng/ml)=80 U/ml[@bib71]Anti-viral activity (Plaque reduction assay)Aqueous root extractHSV-1 strain KOSIC~50~=0.00006%Inhibition of virus replicationAcyclovir[@bib63]HSV-2 strain HG52IC~50~=0.000005%Inhibition of virus replicationAcyclovirAnti-viral activity (Fibroblast/EMCV protection assay)Crude root extractEncephalomyocarditis virus (EMCV)EPs^®^ 7630 (1.6 µg/ml)=100% inhibitionInhibition of cytopathic effect; Modulation of IFN systemIFN-γ (100 U/ml)[@bib30]Antibacterial activity (Microdilution assay)80% methanol tuber extract*Staphylococcus aureus* ATCC 12600MIC=0.683 mg/mlInhibition of bacterial growthNeomycin (MIC=1.302 mg/ml)[@bib51]80% methanol leaf extract*Enterococcus faecalis* ATCC 19433MIC=0.097 mg/mlInhibition of bacterial growthNeomycin (MIC=625 mg/ml)Antibacterial activity (Microdilution assay)Hairy root clones*Bacillus subtilis* ATCC 6051Hairy root clone A4T-C (MIC=390 µg/ml)Inhibition of bacterial growthStreptomycin (MIC=1.56 µg/ml)[@bib10]*Staphylococus aureus* ATCC 12600A4T-C (MIC=780 µg/ml)*Escherichia coli* ATCC 11775A4T-C (MIC=780 µg/ml)Antibacterial activity (microdilution assay)Root extract*Streptococcus pneumoniae*; *Streptococcus pyogenes*; *Streptococcus viridians*; *Staphylococcus aureus*; *Staphylococcus epidermidis*; *Neisseriae* spp.; *Haemophilus influenza* (Clinical strains)MIC=200--1600 μg/mlInhibition of bacterial growth--[@bib75]Antibacterial activity (Microdilution broth method)Aqueous acetone root extract*Staphylococcus aureus* ATCC 25923 incl. multi-resistant strains (1150.93; 1583.93; 999.93; 134.93; 1000.93)MIC=3.3 mg/mlInhibition of bacterial growthBacterial starins resistant to antibiotics *e.g.* ciprofloxacin, erythromycin[@bib30]*Proteus mirabilis* ATCC 14153MIC=3.3 mg/mlAntibacterial activity (Anti-adhesion assay using human HEp-2 cells)EPs^®^ 7630 (aqueous ethanolic extract)*Streptococcus pyogenes* DSM 2071 (serogroup A)45% inhibition (@ 30 µg/ml)Interaction with binding sitesUntreated group[@bib22]Antibacterial activity (Anti-adhesive assay; substrate -- gastric epithelial (AGS) cells)EPs^®^ 7630*Helicobacter pylori* (Clinical strains)EPs^®^ 7630 (50; 100 µg/ml) reduced bacterial attachment to AGS cells by 77% and 91%, respectivelyPrevention of bacterial adhesion to AGS-cell membranesAmoxicillin=no activity[@bib3]Antibacterial activity (Anti-adhesive assay; substrate human stomach epithelial tissue)EPs^®^ 7630*Helicobacter pylori* type I, strain G27Dose-dependent reduction in *Helicobacter pylori* adhesion to human gastric AGS-cell membranes (100% inhibition @ 10 mg/ml)Inactivation of host (mucosal glycoproteins and epithelial mucins) bacterial adhesins interaction3\'-/6\'-Sialyllactose=100% inhibition; *Abelmoschus Esculentus* \>90% inhibition[@bib81]Antibacterial activity (Flow cytometric adhesion assay with human HEp-2 cells and as substrate)EPs^®^ 7630*Streptococcus pyogenes* (Group A streptococci-GAS) DSM 2071 (serogroup A)GAS adhesion to HEp-2 cells reduced by 46% @ 30 µg/mlEPs^®^ 7630 reduces bacterial adhesion to HEp-2 cells by targeting adhesion factors of GASControl (Samples without EPs^®^ 7630): adhesion=80% HEp-2 cells[@bib13]Antibacterial activity (Flow cytometric adhesion assay with BEC as substrate)EPs^®^ 7630*Streptococcus pyogenes* (GAS) DSM 2071 (serogroup A)EPs^®^ 7630 (30 µg/ml): bacterial attachment was7-folder\>controlEnhances attachment of bacteria to decaying BECControl: bacterial attachment to BEC=12.8%[@bib13]Antimycobacterial activity (Microdilution assay)Butanol root extract*Mycobacterium smegmatis* MC^2^ 155MIC 0.156 µg/mlInhibition of bacterial growthCiprofloxacin (MIC=0.125 µg/ml)[@bib41]Scopoletin*Mycobacterium smegmatis* MC^2^ 155MIC=7.81 µg/mlInhibition of bacterial growthUmckalin*Mycobacterium smegmatis* MC^2^ 155MIC=62.5 µg/mlInhibition of bacterial growthCatechin*Mycobacterium smegmatis* MC^2^ 155MIC=31.25 µg/mlInhibition of bacterial growthEpigallocatechin*Mycobacterium smegmatis* MC^2^ 155MIC=7.81 µg/mlInhibition of bacterial growthAntimycobacterial activity (BACTEC 460-radiometric assay)Scopoletin; Umckalin; Catechin; Epigallocatechin*Mycobacterium tuberculosis* ATCC 27294No activity @ 200 µg/mlN/AIsoniazid (@ 0.02 µg/ml[@bib41]Antimycobacterial activity (Microdilution susceptibility assay)EPs^®^ 7630 fatty acids*Mycobacterium aurum* A+Oleic acid (MIC-4 µg/ml); linoleic acid (MIC-2 µg/ml)Inhibition of mycobacterial growthIsoniazid (MIC=0.06 µg/ml)[@bib66]*Mycobacterium smegmatis* ATCC 14468Linoleic acid (MIC-4 mg/ml)Inhibition of mycobacterial growthIsoniazid (MIC=1.0 mg/ml)Antimycobacterial activity (Microdilution assay)EPs^®^ 7630 fatty acids (*n*-hexane extract)*Mycobacterium Aurum* (Clinical strain)Oleic acid (MIC-2 µg/ml); linoleic acid (MIC-2 µg/ml)Inhibition of mycobacterial growth--[@bib68]Antimycobacterial activity (Microplate Alamar blue assay)Crude root extract*Mycobacterium tuberculosis* H~37~Rv ATCC 27294Extract=100 μg/ml (MIC)Inhibition of mycobacterial growthRifampicin (MIC=0.06 μg/ml)[@bib30]Antimycobacterial activity (BACTEC 460-radiometric assay)Crude root extract*Mycobacterium tuberculosis* H~37~Rv ATCC 2729496% Inhibition (\@12.5 µg/ml)Inhibition of mycobacterial growth[@bib30]Antifungal activity80% methanol leaf extract*Candida albicans* ATCC 102310.781 mg/ml (MIC)Inhibition of fungal growthAmphotericin B (MIC=0.488 mg/ml)[@bib51]Antifungal activity (Microbiological killing assay)EPs^®^ 7630 (aqueous ethanolic extract)*Candida albicans* DSM 1386 ATCC 10231EPs^®^ 7630 (30 µg/ml)=31% reduction in viable *C. albicans* cellsIntracellular killing is caused by a positive effect EPs^®^ 7630 on the PBP killing activity--[@bib12]Antifungal activity (Flow cytometry-based, whole blood method)EPs^®^ 7630 (aqueous ethanolic extract)*Candida albicans* DSM 1386 ATCC 10231EPs^®^ 7630 (30 µg/ml)=increased burst-active PBP to 120% after 4 minQuick release of PBP to fight pathogens--[@bib12]Antiparasitic activity (Intracellular leishmanicidal activity)EPs^®^ 7630*Leishmania major* strain LT 52, clone CC-1pXG-GFPEPs^®^ 7630 (0.1--10 μg/ml) Dose-dependent antileishmanial activityStimulation of NO releaseAmphotericin B=1.0 μM[@bib71]Antiparasitic activity (Intracellular leishmanicidal activity)Methanol extract*Leishmania donovani*EC~50~=2.7 µg/mlActivation of leishmanicidal macrophage functionsPentostam (EC~50~=7.9 µg/ml)[@bib26]Petroleum ether extract*Leishmania donovani*EC~50~=\<0.1 µg/mlEthyl acetate*Leishmania donovani*EC~50~=\<0.1 µg/ml*n*-Butanol*Leishmania donovani*EC~50~=\<3.3 µg/mlGallic acid*Leishmania donovani*EC~50~=\<4.4 µg/mlGallic acid methyl ester*Leishmania donovani*EC~50~=\<12.5 µg/mlCoumarims*Leishmania donovani*EC~50~=\>25 µg/mlImmunomodulatory activity (Griess assay)EPs^®^ 7630 (1--30 μg/ml)*Listeria monocytogenes* strain EGD serotype 1/2bEPs^®^7630 (1--30 μg/mL) increased levels of NO; production of IL-1, IL-12, TNF-αBacterial inhibition through the antimicrobial effector molecule -- NOLPS (10 ng/ml)/IFN-γ (100 U/ml)[@bib70]Immunomodulatory activity (Fluorescence-activated cell sorter analysis - FACS)EPs^®^ 7630 (30 μg/ml)*Listeria monocytogenes* strain EGD serotype 1/2bConcentration dependent increase in IL-1, IL-12 and TNF-αCytokine-induced macrophage activationLPS (10 ng/ml)/IFN-γ (100 U/ml)[@bib70]Immunomodulatory activity (Enzyme-linked immunosorbent assay - ELISA)EPs^®^ 7630 (1--30 μg/ml)*Listeria monocytogenes* strain EGD serotype 1/2bTNF-α (*Listeria*-infected BMMΦ)=(11.4--16.0 ng/mL)Cytokine-induced macrophage activationLPS (10 ng/ml)/IFN-γ (100 U/ml)=(9.8±1.1 ng/mL)[@bib70]Immunomodulatory activity (Fibroblast-lysis assay-TNF activity)EPs^®^ 7630*Leishmania donovani*Ethyl acetate fraction (25 µg/ml)=20.2 U/mlCytokine-induced macrophage activationLPS (10 ng/ml)=184 U/ml[@bib26]*n*-Butanol fraction (25 µg/ml)=18.9 U/mlCytokine-induced macrophage activationGallic acid (25 µg/ml)=39 U/mlCytokine-induced macrophage activationGallic acid methyl ester (25 µg/ml)=25.1 U/mlCytokine-induced macrophage activationImmunomodulatory activity (Fibroblast-virus protection assay-IFN activity)EPs^®^ 7630EMCVGallic acid: 12.5 µg/ml=0.4 U/ml; 25 µg/ml=3.7 U/ml; 50 µg/ml=17.9 U/mlInhibition of cytopathic effect; Modulation of IFN systemLPS (10 ng/ml)[@bib26]Immunomodulatory activity (Greiss assay)EPs^®^ 7630*Leishmania donovani*Gallic acid=54 µM (nitric oxide)Induction of anti-infective effector molecule (=NO)LPS 10 ng/ml)=119 µM[@bib26]7-Hydroxy-5,6-dimethoxycoumarin=40.8 µM (nitric oxide)Induction of anti-infective effector molecule (=NO)6,8-Dihydroxy-5,7-dimethoxycoumarin=46 µM (nitric oxide)Induction of anti-infective effector molecule (=NO)Immunomodulatory activity (Reverse transcription-polymerase chain reaction: RT-PCR)EPs^®^ 7630*Leishmania major* LV9EPs^®^ 7630 (50 μg/ml) up-regulation of iNOS, IL-12 and IL-18 mRNA levelsMolecular activation of cytokine gene expressionIFN-γ (100 U/ml)/LPS (10 ng/ml)[@bib74]Immunomodulatory activity (RT-PCR)EPs^®^ 7630*Leishmania major* LV9EPs^®^ 7630 (50 μg/ml) up-regulation of iNOS and cytokine mRNA levelsMolecular activation of cytokine gene expressionIFN-γ (100 U/ml)/LPS (10 ng/ml)[@bib29][^1][^2]Table 2*In vivo* studies in the pharmacological evaluation of *Pelargonium sidoides* DC.**Biological activityExtract/formulationExperimental organismTest organismAdministrationDose rangeActive concentrationResponseControlReference**Antiviral activityEPs^®^ 7630Female BALB/c miceA/Puerto Rico/8/34H1N1 virusInhalation5 mg/kg5 mg/kgIncreased survival of virus-infected miceMice treated with vehicle[@bib72]Anticoagulant activityEPs^®^ 7630Male Sprague--Dawley ratsN/AOral10, 75, 500 mg/kg500 mg/kg p.o.No effect on blood coagulationWarfarin (0.05 mg/kg p.o.)[@bib27]Central nervous system activityEpigallo- and gallocatechin based oligomers of EPs^®^ 7630Male NMRI miceN/A--200 mg/kg200 mg/kgNone to moderate effect on behavioural activityMice treated with vehicle[@bib65]Lipopolysaccharide (LPS) induced sickness behaviourEPs^®^ 7630Male NMRI-miceN/AOral100, 200, 400 mg/kg400 mg/kgComplete counteraction of LPS-induced sickness-behaviourMice treated with vehicle[@bib56][^3]Table 3Clinical studies on *Pelargonium sidoides* DC. and its related pharmaceutical products.**DiseaseStudy designNo. of patientsAge (years)Group sizeDosage /dayDurationOutcomes measuresResultObserved adverse eventsSafetyReference**Acute bronchitisDouble-blind, placebo-controlled clinical trial with one adaptive interim analysis2201--18EPs^®^ 7630=111 vPlacebo=1093×10 Drops (1--6 years) 3×20 drops (6--12 years) 3×30 drops (12--18 years)7 DaysChange in BBS scoreEPs^®^ 7630 (4.4); Placebo (2.9) (*p*\<0.0001)GastrointestinalAll adverse events were non-serious[@bib23]Acute bronchitisRandomized, double-blind, placebo-controlled clinical dose-finding study with 4 parallel treatment groups4006--18EPs^®^ 7630 (30 mg/day)=100 EPs^®^ 7630 (60 mg/day)=99 EPs^®^ 7630 (90 mg/day)=99 Placebo=10130, 60, 90 mg EPs^®^ 76307 DaysChange in BBS scoreEPs^®^ 7630 (30 mg/day)=3.6 EPs^®^ 7630 (60 mg/day)=4.4 EPs^®^ 7630 (90 mg day)=5.5 Placebo=3.3 (*p*\<0.0001)GastrointestinalAll adverse events were non-serious[@bib24]Acute bronchitisRandomised, double-blind, placebo-controlled, multicentre trial217≥18EPs^®^ 7630=108 Placebo=1093×30 Drops7 DaysChange in BBS scoreEPs^®^ 7630 (7.6); Placebo (5.3) (*p*\<0.0001) EPs^®^ 7630-strong antitussive and "anti-fatigue" effectsIncreased erythrocyte sedimentation rateNo serious adverse events recorded[@bib44]Acute bronchitisRandomised, double-blind, placebo-controlled, multicentre study20518--66EPs^®^ 7630=108 Placebo=109 Adults: 18--66 years3×30 Drops7 DaysChange in BBS scoreDecrease in BBS by: EPs^®^ 7630 (7.6) Placebo (5.3); *p*\<0.0001GastrointestinalNo serious adverse events occurred during the study[@bib42]Acute bronchitisProspective, open, multicentre outcomes study*N*=205Mean total score of 5 typical bronchitis symptomsScore decrease 6.1 (baseline)-2.8 (day 7)Not specifiedNo serious adverse effects[@bib45]Acute bronchitismulti-centre, prospective, open observational study20990--93All patients (*n*=2099); Children (3--18 years, *n*=498); infants (\<2 years, N=78)3×10 Drops (\<6 years) 3×20 drops (6--12 years) 3×30 drops (\>12 years)14 DaysChange in BBS scoreBSS decreased from a median of 7.1 at baseline to 1.0 at the 3^rd^ follow-upGastrointestinalAll adverse events were non-serious[@bib46]Acute bronchitisOpen and uncontrolled study7420--12Children (upto 12 years old, N=742)3×5 Drops (0--2 years) 3×10 drops (2--6 years) 3×20 drops (\>6 years)14 DaysChange in BBS scoreDecrease in BBS score from 6.0 (baseline) to 1.4 (end of study) (*p*\<0.001)Exanthema; dyspnoea; diarrhoeaAdverse events-minor and transitory; disorders disappeared in 2 days[@bib18]Acute bronchitisRandomised, Double-blind, placebo-controlled trial124≥18EPs^®^ 7630=64 Placebo=603×30 Drops7 DaysChange in BBS scoreEPs^®^ 7630 (7.2); Placebo (4.9) (*p*\<0.0001)Not specifiedAll adverse events were non-serious[@bib9]Acute bronchitisDouble-blind, placebo-controlled trial468≥18EPs^®^ 7630=233 Placebo=2353×30 Drops7 DaysChange in BBS scoreEPs^®^ 7630 (5.9); Placebo (3.2) (*p*\<0.0001)Gastrointenstinal; nervous system; respiratory and mediastinal; ear and labyrinth compliantsAll adverse events were non-serious[@bib43]Transient hypogammaglobulinemia of infancy (THI)Double-blind, placebo controlled, prospective, monocentric pilot study281--5EPs^®^ 7630=14Placebo=143×30 Drops7 DaysSymptom scoringEPs^®^ 7630 and placebo-no significant difference in symptom scoresNot specifiedNo adverse events[@bib57]Immunomodulatory effectDouble-blind; Placebo-controlled trial2526--56*Pelargonium sidoides* extract=11Placebo=143×30 Drops28 DaysLevel of increase in salivary sIgA concentrationHerbal extract-213 µg/ml; Placebo-41.16 µg/mlNot specifiedNo safety evaluation done[@bib40]Common coldRandomised, double-blind, parallel group, placebo-controlled trial10318--55EPs^®^ 7630=52 Placebo=513×30 drops10 DaysChange in SSIDSSID values: EPs^®^ 7630 (14.6); Placebo (7.6) (*p*\<0.0001)Tracheitis;epistaxisAll adverse events were non-serious[@bib38]Acute rhinosinusitis (of presumably bacterial origin)Randomised; Double-blind, parallel group, placebo-controlled trial10318--60EPs^®^ 7630=51 Placebo=523×60 Drops22 DaysChange in SSSSSS mean decrease: EPs^®^ 7630 (5.5); Placebo (2.5)(*p*\<0.00001)Gastrointestinal; allergic skin reactionAll adverse events were non-serious[@bib2]Asthma attacks during viral infectionsAsthmatic children in randomised study611--14EPs^®^ 7630=30 Control=313×10 drops (1--5 years) 3×20 drops (6--12 years) 3×30 drops (\>12 years)5 DaysSymptom scoreEPs^®^ 7630 group had less frequency of asthma attacks (*p*\<0.05)Not specifiedNo safety evaluation done[@bib67]Chronic obstructive pulmonary disease (COPD)Double-blind, parallel group, placebo-controlled clinical trial200≥18EPs^®^ 7630=99 Placebo=1013×30 Drops24 WeeksTime to first exacerbation of COPDEPs^®^ 7630=57 days; Placebo=43 days (*p*=0.005) EPs^®^ 7630: 37.8% needed antibiotic treatment *vs* 73.3% for placebo (*p*\<0.0001)GastrointestinalAll adverse events were non-serious[@bib47]Acute non-group A beta-hemolytic *streptococcus* tonsillopharyngitisRandomized, double-blind, placebo-controlled trial1436--10EPs^®^ 7630=73 Placebo=70; Children (6--10 years)3×20 Drops6 DaysChange in TSS score from baselineTSS mean decrease: EPs^®^ 7630 (7.1 points); Placebo (2.5 points); (*p*\<0.0001)Not specifiedAdverse events were independent of investigational medication[@bib4][^4]

3.1. *In vitro* studies {#s0020}
-----------------------

*Pelargonium sidoides* extracts have been tested and exhibited good activity against a number of viruses, including influenza A viruses (H1N1, H3N2), coxsackie A9 virus, human coronavirus, respiratory syncytial virus (RSV), parainfluenza virus 3 and herpes simplex viruses (HSV-1, HSV-2) ([Table 1](#t0005){ref-type="table"}). However, the EPs^®^ 7630 phytopharmaceutical had poor activity (IC~50~=\>100 µg/ml) against the highly pathogenic avian influenza A virus (H5N1) ([@bib49]). Notably, the EPs^®^ 7630 extract had high *in vitro* activity against H1N1 (IC~50~=5.4 µg/ml) ([@bib72]) and H3N2 (IC~50~=8.66 µg/ml) ([@bib49]) attesting to its use in respiratory health conditions. The authors noted that the EPs^®^ 7630 extract was more active against enveloped viruses compared to non-enveloped viruses (adenovirus 3, adenovirus 7 and human rhinovirus). Interestingly, antiviral bioactivity (EC~50~) of isolated phenolic constituents against H1N1 increased in the order of complexity of their chemical chain structure as follows: epigallocatechin (42.5 µg/ml)\>gallocatechin (28.4 µg/ml)\>gallocatechin-(4β→8)-gallocatechin (7.3 µg/ml)\>epigallocatechin-(4β→8)-gallocatechin (6.3 µg/ml)\>oligo-/polymeric fraction (2.8 µg/ml) ([@bib72]). The study reported a poor direct virucidal activity of EPs^®^ 7630 (250 µg/ml). Instead the authors discovered that the extract and its phenolic constituents imparted anti-viral activity by interfering with virus binding to host cell receptors and through inhibition of the neuraminidase enzyme. Furthermore, the control of viral infections may occur through the production of interferons (IFNs) by the host cells, suggesting that therapy by *Pelargonium sidoides* may be through the stimulation of the innate immune system (Kolodziej, 2007). Based on the current state of research using *in vitro* models it is clear that the mode of action of *Pelargonium sidoides* in antiviral activity may involve several mechanisms. The mode of action of the antiviral constituents in *Pelargonium sidoides* has also not been explained using *in vivo* models, for example [@bib72] only showed that EPs^®^ 7630 increased survival of H1N1 virus-infected mice, but did not explain the underlying mechanisms involved ([Table 2](#t0010){ref-type="table"}). Further studies incorporating molecular approaches may help to understand the mechanism of action of the antiviral active constituents.

In traditional medicine, extracts of *Pelargonium sidoides* are used to treat bacterial-related conditions such as diarrhoea, dysentery and tuberculosis ([@bib21]). In South Africa, many plant species are used to alleviate symptoms of tuberculosis caused by *Mycobacterium tuberculosis*, the fifth largest cause of mortality in the country ([@bib48]). *Pelargonium sidoides* plant extracts have been tested against *Mycobacterium* species as well as several Gram-positive (*Bacillus subtilis*, *Enterococcus faecalis*, *Staphylococcus aureus*, *Streptococcus pyogenes*) and Gram-negative (*Escherichia coli*, *Proteus mirabilis*, *Helicobacter pylori*) bacteria. Most notably, EPs^®^ 7630 had moderate *in vitro* activity against multi-resistant *Staphylococcus aureus* with a minimum inhibitory concentration (MIC) of 3.3 mg/ml ([@bib30]). The same bacterial strains were resistant to common antibiotics such as ciprofloxacin and erythromycin. This study provided a significant finding and highlighted the importance of *Pelargonium sidoides* as a potential alternative antibacterial remedy at a time when resistance to antibiotics is fast becoming a medical challenge. However, there is need of a paradigm shift towards experimentation that provides more biological insights on the molecular mechanisms involved in the observed *in vitro* activity. A *Pelargonium sidoides* butanol extract had higher activity (MIC=0.156 µg/ml) compared to that of its isolated chemical entities such as umckalin (MIC=62.5 µg/ml) against *Mycobacterium smegmatis* possibly due to synergistic effects ([@bib41]). The efficacy of a natural product may be due to two or more constituents acting synergistically, whereby their respective bioactivities often diminish or disappear upon separation into individual chemical entities ([@bib36]). Synergism of bioactive compounds in phytopharmaceuticals is normally claimed to account for their therapeutic effectiveness ([@bib79]). In particular, polyphenolic compounds in plant extracts are known to increase the pharmacokinetic rate of anti-infective constituents in phytopharmaceuticals thereby enhancing their bioavailability ([@bib78]). In addition, these natural products can also work synergistically with antibiotics thereby improving their overall pharmacokinetic properties against resistant bacterial strains ([@bib62]). However, the moderate MICs suggest that *Pelargonium sidoides* constituents have no direct effect on the bacteria. Thus, further studies have attempted to elucidate the modes of action of its active constituents. [@bib3] and [@bib13] working on *Helicobacter pylori* and *Streptococcus pyogenes*, demonstrated that EPs^®^ 7630 prevents the bacteria from adhering to gastric AGS-cell membranes and HEp-2 cells, respectively. These studies showed that the possible mode of action of the bioactive constituents is through modulation of host-bacteria interactions and phagocytosis, which prevent bacterial attachment to the substrate (gastric and human epithelial cells) thereby rendering the pathogens ineffective. The bioactive constituents of *Pelargonium sidoides* have been shown to specifically target adhesion factors of the bacteria rather than those of the epithelial cell membranes ([@bib11]).

Immunomodulatory activities of *Pelargonium sidoides* and its related phytopharmaceutical medicine may also account for the observed moderate bioactivity against bacteria associated with respiratory diseases through activation of the host cells macrophage machinery. [@bib26] demonstrated that murine macrophages infected with *Leishmania* parasites induced the production of the reactive nitrogen intermediary, inorganic nitric oxide (NO), a known antimicrobial effector molecule. The study showed that gallic acid and the highly oxygenated coumarins, 7-hydroxy-5,6-dimethoxycoumarin (umckalin) and 6,8-dihydroxy-5,7-dimethoxycoumarin were the most potent NO-inducers. [@bib70] further proved that activated macrophages obtained from C57BL/6 WT mice were key components of the antimicrobial immune response against *Listeria monocytogenes* through the production of NO. Compared to the control (2.2 µM), infected cells treated with EPs^®^ 7630 significantly increased release of NO in a dose-dependent response from 1.0 µg/ml (2.8 µM) to 30 µg/ml (5.5 µM). In both models, infected macrophages had a higher NO-inducing effect compared to non-infected macrophages indicating that the nonspecific immune response was triggered under disease attack ([@bib26], [@bib70]). In *Leishmania major*-infected macrophage-like RAW 264.7 cells exposed to EPs^®^ 7630, there was a marked up-regulation of inducible nitric oxide synthase (iNOS) gene expression evaluated by reverse transcription-polymerase chain reaction (RT-PCR) ([@bib29], [@bib74]). In diseased cells, the molecular expression of iNOS in activated macrophages stimulates the production of high levels of NO, which is an antimicrobial effector molecule ([@bib54]). In particular, gallic acid, one of the constituents of the EPs^®^ 7630 ([@bib26]) has been shown to induce prolonged iNOS mRNA expression in *Leishmania*-infected cells. In addition, release of tumour necrosis factor (TNF-α) and interferons (IFN) provided further evidence for cytokine-induced macrophage activation and plays a crucial role in immune defence mechanisms in infected cells ([@bib61]). Experimental data has shown that the TNF-inducing potential of *Pelargonium sidoides* is strongly associated with its phenolic constituents ([@bib31]). The methanol extract of *Pelargonium sidoides* (25 µg/ml) exhibited negligible TNF-inducing potential (\<0.1 U/ml) compared to the moderate activity of the ethyl acetate (20.2 U/ml) and *n*-butanol (18.9 U/ml) fractions ([@bib26]). Most significantly, gallic acid (6.25--50 µg/ml) led to a high dose-dependent increase in TNF-inducing potency (21--43.7 U/ml) of infected cells. [@bib58] also demonstrated the concomitant TNF-α mRNA gene expression in infected cells. On the other hand, gallic acid was shown to increase IFN-α level in *Leishmania*-infected cells ([@bib29]) coupled with the up-regulation of IFN-γ mRNA transcripts ([@bib58], [@bib29]). Most notably, umckalin, the signature chemical entity in *Pelargonium sidoides* exhibited poor cytokine gene expression profiles.

3.2. *In vivo* studies {#s0025}
----------------------

[Table 2](#t0010){ref-type="table"} presents a summary of pharmacological evaluations using *in vivo* animal models. Despite the importance of animal models in the evaluation of pharmacological efficacy, only a few studies have utilised this system for *Pelargonium sidoides* and/or its related formulations. Good research practice for plant-derived medicines dictates that *in vitro* tests should be backed up with *in vivo* and ultimately clinical studies ([@bib20]). More studies on *Pelargonium sidoides* should adopt this approach so as to avoid the pitfalls associated with extrapolating *in vitro* test results to claim *in vivo* activity and efficacy. [@bib14] argued that animal models are indispensable in validating *in vitro* activity because they take into account pharmacokinetic, metabolic and toxicological phenomena. Based on this approach, [@bib83], [@bib73] and [@bib37] used *in vitro* and *in vivo* antiviral models thereby obtaining comprehensive pharmacological data including efficacy and toxicology of several Chinese herbal medicines. Recently, [@bib72] confirmed *in vitro* antiviral activity of EPs^®^ 7630 using an *in vivo* animal model system. Therefore, both *in vitro* and *in vivo* models should be considered in future *Pelargonium sidoides* anti-infective research. In addition, the research can also focus on developing better *in vivo* model systems to elucidate the actual mechanisms involved in the therapeutic processes of *Pelargonium sidoides*, which have so far remained unclear.

3.3. Clinical studies {#s0030}
---------------------

The phytopharmaceutical, EPs^®^ 7630 has undergone numerous clinical evaluations in randomised, double-blind, placebo-controlled trials. Incidentally, it has been clinically evaluated against respiratory-related conditions, namely acute bronchitis, acute rhinosinusitis, common cold, chronic obstructive pulmonary disease and asthma ([Table 3](#t0015){ref-type="table"}). The clinical trials conducted for EPs^®^ 7630 have included patients of all ages. The reported results suggest that the *Pelargonium sidoides* herbal medicine may be effective in the treatment of respiratory infections caused by bacteria and viruses. Among the common respiratory tract infections, most of the clinical studies have evaluated the phytopharmaceutical against acute bronchitis in placebo-controlled studies. Acute bronchitis is characterised by acute inflammation of the respiratory tract and is caused by viral infections in 95% of the cases ([@bib45]). However, more clinical studies have to be done to determine its efficacy in the treatment of other common respiratory diseases. Despite the limited benefit of antibiotic therapy for acute bronchitis, they are prescribed in 60--80% of the cases ([@bib42]). Against this background, more appropriate treatment options are required so as to prevent the overuse and/or abuse of antibiotics. In this regard, phytopharmaceuticals such as *Pelargonium sidoides*-based products may provide an alternative therapeutic option in the treatment of respiratory tract infections and related ailments.

3.4. Safety evaluation {#s0035}
----------------------

It is of paramount importance that medicinal plants and phytopharmaceuticals are safe and do not cause undesirable side effects in patients. However, despite its long history of use in traditional medicine, there is a dearth of scientific information pertaining to the safety evaluation of *Pelargonium sidoides*. The *Pelargonium sidoides* extract, EPs^®^ 7630, did not cause obvious toxic effects in mice as there were no significant differences in body weight, body temperature as well as organ weight (lungs, liver, spleen, kidneys) between the treatment and control groups ([@bib72]). Based on clinical data, the tolerability of treatment with EPs^®^ 7630 has been shown to be good in both adults and children ([Table 3](#t0015){ref-type="table"}). Nevertheless, some of the commonly reported adverse events included gastrointestinal complaints such as diarrhoea ([@bib43], [@bib46], [@bib47], [@bib18], [@bib42], [@bib2], [@bib24], [@bib23]), nervous system complaints ([@bib43]), respiratory and mediastinal ailments ([@bib43]), ear and labyrinth complaints ([@bib43]), exanthema ([@bib18]), tracheitis and epistaxis ([@bib38]) and allergic skin reactions ([@bib2]). Recently, a clinical study by [@bib69] concluded that *Pelargonium sidoides* did not reveal evidence of hepatotoxicity. However, even though the adverse events in most clinical studies have been reported as non-serious, more rigorous studies are still required to ascertain the safety of *Pelargonium sidoides* and its related formulations. In addition, further toxicological studies involving toxicity and mutagenic tests need to be done to evaluate the safety of this plant. Although the benefits of medicinal plants are widely acknowledged, the need for safety evaluation remains critical so as to distinguish between toxic effects and pharmacological efficacy of plant extracts ([@bib1]). Based on the numerous studies reported in the current review, there is compelling experimental and clinical evidence to suggest that *Pelargonium sidoides* may be efficacious against respiratory tract infections and may be safe for both adults and children, but more stringent toxicological studies are required. [@bib77] have comprehensively discussed the various methods that are used in evaluating the safety of medicinal plants.

4. Commercial potential and world marketing {#s0040}
===========================================

Besides its local use as a multipurpose traditional remedy, *Pelargonium sidoides* has evolved into an international phytopharmaceutical. The commercialisation of *Pelargonium sidoides* dates back to the early 1900s when the plant was introduced in Europe as a tuberculosis remedy by Charles Henry Stevens after being reportedly cured by a traditional healer in Lesotho ([@bib5], [@bib7], [@bib82]). The growing international demand for the *Pelargonium sidoides* root extract has led to an increase in the number of gatherers as well as the volume of harvested plant materials. Its evolution from a traditional medicine exclusive to southern Africa, mainly South Africa and Lesotho, into a successful phytopharmaceutical (Umckaloabo^®^) has created 'the *Pelargonium* industry' involving a network of harvesters, local buyers and processors and international pharmaceutical manufacturers, such as Dr. Willmar Schwabe GmbH & Co., KG Pharmaceuticals (Karlsruhe, Germany). *Pelargonium* trade has evolved from a largely unregulated to a more formalised industry over the past 20 years ([@bib82]). An unknown number of harvesters in the Eastern Cape (South Africa) and Lesotho collect and sell the plant materials to local intermediary buyers ([@bib76], [@bib55]). The organisation of trade in medicinal plants normally involves a chain of local dealers buying plant materials from local collectors and eventually selling to larger trading and export companies ([@bib39]). In the Eastern Cape, Gowar Enterprises collects and supplies the *Pelargonium sidoides* tuberous roots to another intermediary, BZH Import and Export, responsible for drying, shredding, packaging and onward routing to Parceval Pharmaceuticals, which exports the materials to the end-product manufacturer in Germany ([@bib76]). In Lesotho, Bophelo Processing is responsible for collecting, processing and supplying of the tubers to Parceval Pharmaceuticals ([@bib82]). The processing of the raw materials obtained from developing economies involved in the medicinal plant trade is still predominantly undertaken in European countries by end-product manufacturers ([@bib39]) and this also applies to *Pelargonium sidoides*.

The commercial success of Umckaloabo^®^ provides a good example of what can be achieved with a well-directed research and development initiative and astute marketing ([@bib15]). Most of the harvesters mainly rely on wild collection of *Pelargonium sidoides* for their livelihoods due to limited alternative economic opportunities in these communities. Amidst the overall commercial success of the *Pelargonium* trade, questions have been asked about the possible vulnerability of the harvesters and their lack of bargaining power arising from the monopolistic marketing chain ([@bib76]). Large trading companies have significant control over the pricing system due to their central role in the medicinal plant trade coupled to large scale purchases and ownership of critical infrastructure to perform several functions including quality control ([@bib39]). However, despite these challenges related to beneficiation equity from medicinal resources, lessons arising from the *Pelargonium sidoides* case study are clearly invaluable for future natural product research and development programmes in developing countries. An increasing number of medicinal plant suppliers in China, India, Mexico and Malaysia are now exporting processed products to end-product manufacturers in Western countries ([@bib39]). The '*Pelargonium* industry' may have to evolve in tandem to this growing trend in the medicinal plant trade.

5. Biotechnology applications in *Pelargonium sidoides* conservation {#s0045}
====================================================================

The increasing commercial demand for *Pelargonium sidoides* on the international market has led to localised uncontrolled, indiscriminate and sometimes illegal harvesting of wild plants ([@bib35], [@bib34], [@bib82]). The escalation in demand can cause irreparable reductions to wild populations ([@bib10]), which may result in a biodiversity threat to *Pelargonium sidoides*. However, the conservation status of *Pelargonium sidoides* was recently revised from 'declining' ([@bib60]) to 'least concern' ([@bib59]). In Lesotho, the conservation status of *Pelargonium sidoides* has not been evaluated. In addition, the plant is not listed on either the International IUCN Red List of Threatened Species or Convention on International Trade in Endangered Species (CITES) database ([@bib55]). There is a conspicuous lack of comprehensive data on annual harvested and traded volumes of *Pelargonium sidoides*. Varying estimates derived from data collected through interviews have been reported in literature. The estimates of annual harvested fresh material range from 9 to 45 t ([@bib55]) and 26--440 t ([@bib76]). Despite this lack of accurate data, tight conservation regulations have been formulated to curb uncontrolled harvesting in South Africa ([@bib55]). Notwithstanding the occasional financial returns obtained by the local communities, the overexploitation of the resource may affect its availability in the future. In the Eastern Cape, the plants had a slow regeneration rate, which was significantly lower than the initial harvest after the second year ([@bib34]). To meet the ever-expanding demand in international trade of raw materials, *Pelargonium sidoides* may have to be cultivated on a large scale. Currently, the plant is only cultivated on a small, negligible scale ([@bib10]). There are also limitations in the use of seed propagation, due to their low viability coupled with low germination ([@bib35]).

Alternatively, biotechnology tools such as plant tissue culture ( [Fig. 1](#f0005){ref-type="fig"}D) may play a critical role in the provision of genetically uniform clones for the *Pelargonium* industry ([@bib51]). Recently, [@bib32], [@bib52] and [@bib53] reported on micropropagation and acclimatisation procedures with the capacity to produce millions of uniform *Pelargonium sidoides* clones throughout the year. There is a long history of the commercial production of high-value phytochemicals using tissue culture systems ([@bib8]). However, a major challenge with the cultivation of medicinal plants is the perception that such plants do not produce a similar quality of bioactive compounds as wild plants. [@bib80] and [@bib51] showed that greenhouse produced plants had similar bioactive compounds as wild plants in terms of the umckalin (6-hydroxy-5,7-dimethoxycoumarin) and phenolic compounds, respectively. In addition, extracts of greenhouse and wild plants exhibited comparable antimicrobial and antioxidant properties ([@bib51]). In the long term, the production of Umckaloabo^®^ may have to be based on plant material produced under consistent cultivation practices. Such cultivated material produced under controlled environmental conditions is preferred for the phytopharmaceutical industry as it minimises qualitative and quantitative variations in the composition of natural products ([@bib39]). In addition, the quality of phytopharmaceuticals can be improved by the use of genetically uniform clones, which eliminates problems associated with product adulteration ([@bib62]).Fig. 1*Pelargonium sidoides*. (a) Young tuberous roots; (b) a flowering plant; (c) cross section of a tuberous root; and (d) high shoot multiplication in a plant tissue culture system.Fig. 2Chemical structures of signature constituents found in *Pelargonium sidoides* DC.: Gallic acid (1); 7-hydroxy-5,6-dimethoxycoumarin (2); and 6,8-dihydroxy-5,7-dimethoxycoumarin (3); 6-Methoxy-7-(sulfooxy)-2H‑1-benzopyran-2-one (4); 6,8-Bis(sulfooxy)-7-methoxy-2H-1-benzopyran-2-one (5); 7-Hydroxy-6-methoxy-8-(sulfooxy)-2H-1-benzopyran-2-one (6); 8-Hydroxy-7-methoxy-6-(sulfooxy)-2H-1-benzopyran-2-one (7).

On the other hand, the future pharmaceutical production of Umckaloabo^®^ may also eventually depend on the application of bioreactor technology in the synthesis of *Pelargonium sidoides* bioactive compounds. [@bib10] demonstrated the ability of transgenic *Pelargonium sidoides* hairy root cultures, transformed using *Agrobacterium rhizogenes*, to produce the desired bioactive pharmaceutical compounds. The authors concluded that the system has immense potential as a conservation strategy for this medicinally important plant. However, there is a possibility that phytotherapeutics produced using biotechnology may not be readily acceptable by consumers of 'natural' medicines. Notwithstanding these concerns, it may be inevitable that biotechnology will play a key role in the production of plant-derived pharmaceutical compounds in the future. Hairy root cultures which are transformed using *Agrobacterium rhizogenes* often sustain stable and high productivity in plant growth regulator-free medium ([@bib8]). Thus, the use of biotechnology approaches can allow for ease of standardisation of the chemical constituents of the phytopharmaceutical thereby guaranteeing consistent quality of the end-product. Overall, this will help to avert the current plant biodiversity conservation dilemma arising from overharvesting practices of wild populations.

6. Conclusions {#s0050}
==============

Despite the emergence, in recent times, of high-throughput screening of synthetic chemical libraries as an alternative technology for the pharmaceutical industry, natural products remain a vital component in drug discovery. In particular, medicinal plants offer several advantages as potential sources of both novel chemical entities and phytopharmaceuticals. The pharmacological activities that have been demonstrated in various *in vitro*, *in vivo* and clinical studies indicate that *Pelargonium sidoides* possesses moderate direct anti-infective properties but highly notable immunomodulatory activity. In addition, *Pelargonium sidoides* root extract is effective and well tolerated in the treatment of respiratory-related infections. Based on both experimental and clinical pharmacological evidence, the transformation of *Pelargonium sidoides* from a traditional medicine to a successful phytopharmaceutical provides a compelling argument for the continued exploration of medicinal plants and indigenous medical systems for the next generation of phytopharmaceuticals. Even though significant milestones have been achieved in *Pelargonium sidoides* pharmacological research, further studies are still needed to fully elucidate the mechanisms of action and the biological principles underlying its therapeutic capacity. Most notably, the bulk of the pharmacological research on *Pelargonium sidoides* has been skewed towards respiratory tract infections at the expense of ailments for which the plant is used in Traditional African Medicine. Clinical research should also focus on other respiratory tract infections besides acute bronchitis, which has so far attracted the most attention. Furthermore, there is lack of conclusive data on the toxicological properties of *Pelargonium sidoides* despite having been used in traditional medicine for a long time. Stringent evaluation of the toxicological properties of *Pelargonium sidoides* is of paramount importance given its extensive use in medicinal formulations.

In the long term, the successful commercialisation of this southern African medicinal plant must be viewed in a much wider and holistic context that includes conservation-friendly practices and the sustainable supply of raw materials. In that context, the sustenance of the *Pelargonium sidoides* phytopharmaceutical industry will require innovative approaches, which utilise biotechnology tools such as plant tissue culture and bioreactors for the production of genetically uniform clones and therapeutic secondary metabolites, respectively.
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[^1]: AGS=gastric epithelial cells; BEC=buccal epithelial cells; BMM*Φ*=Murine bone marrow-derived macrophages; ELISA=enzyme-linked immunosorbent assay; EMCV=Encephalomyocarditis virus; FACS=fluorescence-activated cell sorter analysis; GAS=Group A-streptococci; GFP=green fluorescent protein; Hep=Human epithelial cells; H1N1, H3N2=Influenza A virus strains; HSV=Herpes simplex virus type; IFN=interferon; IL=interleukin; LPS=Lipopolysaccharides; MIC=minimum inhibitory concentration; NO=inorganic nitric oxide; iNOS=inducible nitric oxide synthase; RSV=Respiratory syncytial virus; PBP=human peripheral blood phagocytes; RT-PCR=reverse transcription-polymerase chain reaction; TNF=tumour necrosis factor.

[^2]: EPs^®^ 7630=liquid herbal drug preparation of the root of *Pelargonium sidoides* (drug/extract ratio of 1:8--10) using aqueous ethanol (11% (m/m)) as extraction solvent (Conrad et al., 2007a,b).

[^3]: EMCV=encephalomyocarditis virus; LPS=lipopolysaccarides; N/A=not applicable; NO=nitric oxide; Warfarin=3-(a-acetonylbenzyl)-4-hydroxy-coumarin.

[^4]: BBS=Bronchitis Symptom Score; COPD=Chronic obstructive pulmonary disease; sIgA=secretory immunoglobulin A; SSID=Symptom Intensity Differences; SSS=Sinusitis Severity Score; THI=Transient hypogammaglobulinemia of infancy; TSS=Tonsillopharyngitis Severity Score.
